Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction
Source : https://www.jstage.jst.go.jp/article/ihj/advpub/0/advpub_22-151/_article
It was unclear whether there are discrepancies among the efficacy and safety of different doses of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF). The aim of...
Conclusions: The results from this study suggested that 25 mg of empagliflozin might be better than 10 mg in improving heart function in HFrEF patients, and the safety profiles of 25 mg and 10 mg of empagliflozin are comparable. Further studies are expected to substantiate our speculations.
Share
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36087309/
doi: 10.1002/ejhf.2677. Online ahead of print. 1 Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Kirrberger Str.1, 66421 Homburg/Saar, Germany and Cape Heart Institute, Cape Town, SA. 2...
Conclusions: RHR associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events. This article is protected by copyright. All rights reserved.
Share
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36066557/
In patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no longer evident after 90 days. Acute renal events were similar in...
Conclusion: In patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no longer evident after 90 days. Acute renal events were similar in both groups. The clinical benefit of empagliflozin was consistent regardless of baseline renal function.
Share
Cumulative Complexity: A qualitative analysis of patients' experiences of living with heart failure with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36073202/
The constellation of HFpEF, multimorbidity and aging creates many demands that people with HFpEF are expected to manage. Concurrently, the same syndromes threaten their ability to physically enact this work....
Conclusions: The constellation of HFpEF, multimorbidity and aging creates many demands that people with HFpEF are expected to manage. Concurrently, the same syndromes threaten their ability to physically enact this work. Patients' recollections of their interactions with health professionals suggest there is widespread misunderstanding of HFpEF,...
Share
Impact of breakthrough trials on prescription trends of sodium-glucose cotransporter-2 inhibitors in Japan: An interrupted time-series analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36068684/
The breakthrough trials increased prescription rates not only for patients to whom the trial results could be extrapolated but also for those in whom trial benefits were not certain. Our...
Conclusions: What is new and conclusion: The breakthrough trials increased prescription rates not only for patients to whom the trial results could be extrapolated but also for those in whom trial benefits were not certain. Our findings suggest that information about breakthrough trials may need to be provided along with data on trial result...
Share